3:00 PM (PT)
-
The financing and partnering environment for biotech has shifted significantly in recent years. Investors and partners have increasingly prioritized tangible, de-risked assets that offer compelling therapeutic differentiation and a product roadmap. As a result, the “product-first” model dominates, where clear positioning, validated biology, and a defined regulatory and commercial path are essential to secure financing or partnership interest. Yet companies that can balance a near-term, product-focused strategy with the broader potential of their pipeline are emerging as success stories. Attendees will hear how these companies show that a focused lead asset and a thoughtfully developed pipeline are not mutually exclusive but mutually reinforcing. Their ability to communicate both an immediate value proposition and a credible path to future growth is reshaping how investors assess risk and opportunity in early-stage and emerging biotech ventures.Breakout Session 25ABC
3:00 PM (PT)
-
As life sciences innovation becomes increasingly global, many emerging biotech ecosystems continue to face barriers to accessing the capital, infrastructure, and networks that define established hubs like Kendall Square. This session explores how structured “exchange” programs can create intentional pathways for international startups to integrate into leading biotech ecosystems, gain exposure to entrepreneurial best practices, and accelerate their growth. By enabling cross-border collaboration, these programs not only support international founders but also strengthen host ecosystems through new ideas, technologies, and partnerships. Attendees will hear from leaders actively building these global bridges and walk away with actionable insights on how to design, support, or participate in initiatives that drive sustainable global biotech innovation.Breakout Session 30ABC
1:45 PM (PT)
-
This session will explore ARPA-H’s unique SBIR/STTR funding opportunities and the distinctive commercialization support designed to propel breakthrough companies forward. Attendees will hear firsthand from ARPA-H funded small business performers about their experiences leveraging tailored industry experts and acceleration services to drive their ideas from early-product to patient impact. The discussion will provide an insider’s view from investors on navigating market success in a rapidly evolving sector, including how to combine sources of capital in a challenging environment. Expect to leave with practical strategies and fresh perspectives on ARPA-H’s small business program, open funding opportunities, and the dynamic support ecosystem designed to maximize entrepreneurial impact in health innovation. This program provides an onramp to broader agency initiatives, seeding new ideas, and accelerating solutions that advance ARPA-H's mission.Breakout Session 30ABC
3:00 PM (PT)
-
This panel discussion addresses a critical paradox in biotechnology investment - while female-founded biotech’s demonstrate superior returns, they receive less than 3% of venture funding. This session features four pioneering founders currently building transformative "zero-to-one" companies - those creating entirely new market categories rather than competing in existing spaces. Panelists represent diverse biotech innovations spanning hibernation-based therapeutics, non-invasive vital sign monitoring, epigenetic gene therapies, and gravity-agnostic biotools. This session provides data-driven insights into the funding landscape while delivering actionable strategies for investors, a roadmap from the bench to the boardroom for scientists, understanding emerging technologies that could disrupt traditional approaches for industry veterans, and tactical advice to entrepreneurs from fellow founders building in the hardest environment.Breakout Session 30ABC
4:15 PM (PT)
-
Back by popular demand, this high-impact session returns to BIO and will guide health and science executives through a proprietary framework developed by LaVoieHealthScience: The LHS Fifteen-Slide Presentation®, a disciplined structure that drives clarity, focus, and momentum. These methodologies are designed to help companies clearly articulate the company value proposition, market problem, value solution, competitive differentiation, regulatory approach, and financial vision within a concise 15-slide structure.Breakout Session 30ABC
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}